Research Highlights:

• Edoxaban, a medication taken orally to prevent blood clots from forming, was found to be as effective and safe for stroke and blood clot prevention in patients after heart valve replacement surgery as warfarin, the current standard treatment.
• Unlike warfarin, edoxaban does not require regular blood tests to monitor clotting activity and does not interact with food or other medications, which simplifies treatment for patients, researchers noted.
• Note: The study featured in this news release is a research abstract. Abstracts presented at American Heart Association’s scientific meetings are not peer-reviewed, and the findings are considered preliminary until published as full manuscripts in a peer-reviewed scientific journal.

Embargoed until 8:35 a.m. CT/9:35 a.m. ET, Sunday, Nov. 17, 2024

This news release contains updated information from the researcher that was not in the abstract.

(NewMediaWire) - November 17, 2024 - CHICAGO — Edoxaban, an oral anticoagulant, was equally or more effective than warfarin in reducing the risk of stroke and blood clots for patients after heart valve replacement surgery, according to preliminary late-breaking science presented today at the American Heart Association’s Scientific Sessions 2024. The meeting, Nov. 16-18, 2024, in Chicago, is a premier global exchange of the latest scientific advancements, research and evidence-based clinical practice updates in cardiovascular science.

Patients who receive a heart valve replacement are well-known to be at a high risk for stroke, blood clots and deep vein thrombosis, especially during the weeks immediately after surgery. Current treatment guidelines recommend anticoagulant therapy with medication to prevent and treat blood clots.

People who receive a mechanical heart valve require lifelong anticoagulant therapy to prevent thrombus (blood clot) formation on the valve. Patients who receive a bioprosthetic (made with human or animal tissue) heart valve typically need anticoagulants for three to six months after surgery.

The standard medication for anticoagulation in these patients is warfarin, which decreases the body’s ability to form blood clots by blocking the formation of clotting factors dependent on vitamin K.

“Currently, we can use only vitamin K antagonists such as warfarin for patients early after bioprosthetic valve surgery,” said lead study author Chisato Izumi, M.D., Ph.D., of the National Cerebral and Cardiovascular Center in Suita, Japan. “However, warfarin has a narrow therapeutic range requiring frequent blood testing to monitor clotting activity, and it also interacts with other medications and food, which can be a challenge for patients and the health care professionals treating them.”

The ENBALV trial evaluated the effectiveness and safety of edoxaban, an oral anticoagulant that was approved by the FDA in 2015 for patients with non-valvular atrial fibrillation, compared to warfarin within three months after bioprosthetic valve surgery. Edoxaban works by blocking factor Xa, a clotting factor that plays a key role in the coagulation (blood clotting) process. Edoxaban is taken in a fixed dose and has a predictable pharmacokinetic profile, which means that its effects are not impacted by diet or other medications.

The randomized, multi-center trial included approximately 400 adults in Japan who had bioprosthetic heart valve replacement surgery at the aortic and/or mitral position. Researchers randomized the participants into two equal groups to receive either edoxaban or warfarin for 12 weeks after surgery.

The analysis found:

• Edoxaban was equally or more effective than warfarin at preventing stroke and blood clots: 0.5% of patients receiving edoxaban had a stroke or systemic embolism, compared to 1.5% of patients receiving warfarin.
• Major bleeding occurred in 4.1% of the edoxaban group and in 1% of the warfarin group. However, no fatal bleeding or intracranial hemorrhage was observed in patients treated with edoxaban, whereas one fatal cerebral hemorrhage occurred in the warfarin group.
• Intracardiac thrombus (a blood clot in the heart) did not occur in any of the patients in the edoxaban group, but did occur in 1% of patients in the warfarin group.
• Patients who received edoxaban did experience higher instances of gastrointestinal bleeding compared to patients who received warfarin (2.1% vs. 0%, respectively).

“Our findings show that edoxaban could help prevent blood clots and stroke as effectively as warfarin, indicating it is a viable post-surgery treatment alternative to consider for patients who have received a bioprosthetic heart valve replacement,” Izumi said. “Edoxaban could make life easier for patients recovering from heart valve surgery. Since this medication does not require regular blood tests to monitor anticoagulation activity and can be taken in a fixed dose, without fears of interaction with food or other medications, it reduces the burden on patients and improves their quality of life, especially in those crucial first few months after surgery.”

The researchers said future research is needed to understand which patients have the highest risk of bleeding with the use of edoxaban and how to mitigate this risk while still offering effective treatment options in post-surgery treatment and recovery. The effectiveness and safety of other direct oral anticoagulants besides edoxaban also warrants further investigation.

The study had several limitations including that it was open label, meaning all health care professionals and participants knew which medication they were receiving, which may have resulted in bias. In addition, the study did not include patients undergoing transcatheter valve replacements (aortic valve replacement with a man-made valve).

Study details, background and design:

• The study enrolled 410 patients at 24 institutions in Japan who had bioprosthetic valve replacement at the aortic and/or mitral position between May 2022 and January 2024; 389 patients were included in the final analysis.  
• Participants were randomized to receive either edoxaban (60 mg or 30 mg taken orally, once daily) or warfarin (administered orally, with dosing adjusted by monitoring the time taken for the patient’s blood to clot) for 12 weeks after surgery.
• Patients were ages 41-84 years old, with an average age of 73 years. The edoxaban group was 51% male and 49% female; the warfarin group was 63% male and 37% female.

Co-authors, disclosures and funding sources are listed in the abstract.  

Statements and conclusions of studies that are presented at the American Heart Association’s scientific meetings are solely those of the study authors and do not necessarily reflect the Association’s policy or position. The Association makes no representation or guarantee as to their accuracy or reliability. Abstracts presented at the Association’s scientific meetings are not peer-reviewed, rather, they are curated by independent review panels and are considered based on the potential to add to the diversity of scientific issues and views discussed at the meeting. The findings are considered preliminary until published as a full manuscript in a peer-reviewed scientific journal.

 The Association receives funding primarily from individuals; foundations and corporations (including pharmaceutical, device manufacturers and other companies) also make donations and fund specific Association programs and events. The Association has strict policies to prevent these relationships from influencing the science content. Revenues from pharmaceutical and biotech companies, device manufacturers and health insurance providers and the Association’s overall financial information are available here.

Additional Resources:

• Multimedia is available on the right column of the release link
• Link to abstract; and AHA Scientific Sessions 2024 Online Program Planner
• AHA news release: AI may accurately detect heart valve disease and predict cardiovascular risk (Nov. 2023)
• AHA news release: CAROL Act will prioritize research on heart valve disease (Dec. 2022)
• AHA news release: Updated guideline for heart valve disease spotlights less invasive treatments (Dec. 2020)
• AHA health information: Heart Valve Disease
• AHA health information: Heart Valve Disease Risks, Signs and Symptoms
• AHA health information: Heart Valve Disease Resources
• For more news at AHA Scientific Sessions 2024, follow us on X @HeartNews, #AHA24

###

About the American Heart Association

The American Heart Association is a relentless force for a world of longer, healthier lives. We are dedicated to ensuring equitable health in all communities. Through collaboration with numerous organizations, and powered by millions of volunteers, we fund innovative research, advocate for the public’s health and share lifesaving resources. The Dallas-based organization has been a leading source of health information for a century. During 2024 - our Centennial year - we celebrate our rich 100-year history and accomplishments. As we forge ahead into our second century of bold discovery and impact, our vision is to advance health and hope for everyone, everywhere. Connect with us on heart.org, Facebook, X or by calling 1-800-AHA-USA1.

For Media Inquiries and AHA Expert Perspective:

AHA Communications & Media Relations in Dallas: 214-706-1173; ahacommunications@heart.org

Amanda Ebert: Amanda.Ebert@heart.org   

For Public Inquiries: 1-800-AHA-USA1 (242-8721)

heart.org and stroke.org